Katy Lísias Gondim Dias de Albuquerque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Katy Lísias Gondim Dias de Albuquerque has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Chahira Taha Mahd Ibrahim Issa
Universidade Federal da Paraíba, Brasil; Sociedade Brasileira de Estudos de Cannabis Sativa, Brasil
2 shared publications João Paulo Mendes dos Santos
Federal University of Paraíba João Pessoa Paraíba Brazil
2 shared publications- Nelson Torro-Alves
Universidade Federal da Paraíba
2 shared publications - Ricardo Dias de Castro
Universidade Federal da Paraíba, Brasil
2 shared publications Wandersonia Moreira Brito Medeiros
Federal University of Paraíba João Pessoa Paraíba Brazil
2 shared publicationsAmanda Gleiciane de Lima Oliveira
Federal University of Paraíba João Pessoa Paraíba Brazil
1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Wiley in Autism Research
- Vol. 19 (10) , e70353
Effects of Cannabidiol‐Rich Cannabis Oil on Facial Expression Recognition and Theory of Mind in Children With Autism Spectrum Disorder: A Randomized Clinical Trial
To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)‐rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD). This post hoc subanalysis included children from a double‐blind, randomized, placebo‐controlled trial who completed social cognition assessments at baseline and after treatment. Participants received CBD‐rich cannabis oil or placebo for 12 weeks. Facial expression recognition and theory of mind were assessed using neuropsychological tasks. Between‐group differences were evaluated using the Mann–Whitney U test, whereas within‐group changes were assessed using the Wilcoxon signed‐rank test. Nineteen Brazilian children with ASD were included (72.7% male; mean age, 7.82 years). Within‐group analyses showed significant improvements in facial expression recognition ( p = 0.030) and verbal theory of mind ( p = 0.016) after treatment in the CBD group, whereas corresponding changes in the placebo group were not statistically significant. However, between‐group comparisons showed no significant differences after treatment in facial expression recognition ( p = 0.527) or verbal theory of mind ( p = 0.901). Total theory of mind scores improved significantly within both groups, with no significant between‐group difference ( p = 0.967). Although significant within‐group improvements in facial expression recognition and verbal theory of mind were observed following CBD‐rich cannabis oil treatment, these changes were not significantly different from those observed with placebo. Given the small sample size and exploratory post hoc design, these findings should be interpreted cautiously and do not establish a treatment effect of CBD on social cognition in children with ASD. Trial Registration: Brazilian Clinical Trials Registry (ReBEC), RBR‐5wr2cqq (UTN: U1111‐1261‐4178), accessible at https://ensaiosclinicos.gov.br/rg/RBR‐5wr2cqq
- 26 August 2026
- Published by Wiley in Autism Research
- Vol. 19 (10) , e70353
Open AccessEffects of Cannabidiol‐Rich Cannabis Oil on Facial Expression Recognition and Theory of Mind in Children With Autism Spectrum Disorder: A Randomized Clinical Trial
To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)‐rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD). This post hoc subanalysis included children from a double‐blind, randomized, placebo‐controlled trial who completed social cognition assessments at baseline and after treatment. Participants received CBD‐rich cannabis oil or placebo for 12 weeks. Facial expression recognition and theory of mind were assessed using neuropsychological tasks. Between‐group differences were evaluated using the Mann–Whitney U test, whereas within‐group changes were assessed using the Wilcoxon signed‐rank test. Nineteen Brazilian children with ASD were included (72.7% male; mean age, 7.82 years). Within‐group analyses showed significant improvements in facial expression recognition ( p = 0.030) and verbal theory of mind ( p = 0.016) after treatment in the CBD group, whereas corresponding changes in the placebo group were not statistically significant. However, between‐group comparisons showed no significant differences after treatment in facial expression recognition ( p = 0.527) or verbal theory of mind ( p = 0.901). Total theory of mind scores improved significantly within both groups, with no significant between‐group difference ( p = 0.967). Although significant within‐group improvements in facial expression recognition and verbal theory of mind were observed following CBD‐rich cannabis oil treatment, these changes were not significantly different from those observed with placebo. Given the small sample size and exploratory post hoc design, these findings should be interpreted cautiously and do not establish a treatment effect of CBD on social cognition in children with ASD. Trial Registration: Brazilian Clinical Trials Registry (ReBEC), RBR‐5wr2cqq (UTN: U1111‐1261‐4178), accessible at https://ensaiosclinicos.gov.br/rg/RBR‐5wr2cqq
- Open Access
- 22 March 2025
- Published by Sociedade Brasileira de Medicina de Familia e Comunidade (SBMFC) in Revista Brasileira de Medicina de Família e Comunidade
- Vol. 20 (47) , 4567
Acompanhamento clínico de cinco crianças com transtorno do espectro autista que usam óleo de cannabis full spectrum como terapêutica complementar
Introdução: O Transtorno do Espectro Autista (TEA) caracteriza-se por déficits na comunicação e na interação social, além de comportamentos repetitivos e restritivos, geralmente manifestados por volta dos 3 anos. Objetivos: Avaliar a resposta terapêutica de cinco pacientes pediátricos com TEA que utilizaram óleo de cannabis full spectrum rico em canabidiol (CBD) 20 mg/ml associado ao tratamento medicamentoso convencional, acompanhados na Atenção Primária à Saúde no primeiro semestre de 2024. Métodos: Realizou-se um estudo observacional e descritivo, do tipo série de casos, baseado em busca ativa em prontuários digitais. Utilizaram-se instrumentos validados para diagnóstico e avaliação clínica (Childhood Autism Rating Scale - CARS e Autism Treatment Evaluation Checklist - ATEC), além de roteiro semiestruturado fundamentado na Case Report (CARE checklist), permitindo a coleta de dados essenciais sobre a evolução dos pacientes que faziam uso complementar do óleo de cannabis. Resultados: Dos cinco pacientes, três eram meninos e duas meninas, entre 5 e 11 anos. Dois foram classificados com autismo grave e três com autismo leve a moderado. A média de idade ao diagnóstico foi de 42,6 meses, e o uso de CBD durou, em média, 7,4 meses. Todos apresentaram melhora expressiva em sintomas como agressividade, insônia, hiperatividade, interação social, comportamentos repetitivos, seletividade alimentar e concentração. As medicações associadas incluíram risperidona, clorpromazina, lamotrigina e topiramato, sendo a risperidona a mais utilizada. Conclusão: O óleo de cannabis rico em CBD demonstrou efeitos terapêuticos positivos em pacientes com sintomas persistentes do TEA, sem registro de eventos adversos relacionados ao seu uso inicial.
- 22 March 2025
- Published by Sociedade Brasileira de Medicina de Familia e Comunidade (SBMFC) in Revista Brasileira de Medicina de Família e Comunidade
- Vol. 20 (47) , 4567
Open AccessAcompanhamento clínico de cinco crianças com transtorno do espectro autista que usam óleo de cannabis full spectrum como terapêutica complementar
Introdução: O Transtorno do Espectro Autista (TEA) caracteriza-se por déficits na comunicação e na interação social, além de comportamentos repetitivos e restritivos, geralmente manifestados por volta dos 3 anos. Objetivos: Avaliar a resposta terapêutica de cinco pacientes pediátricos com TEA que utilizaram óleo de cannabis full spectrum rico em canabidiol (CBD) 20 mg/ml associado ao tratamento medicamentoso convencional, acompanhados na Atenção Primária à Saúde no primeiro semestre de 2024. Métodos: Realizou-se um estudo observacional e descritivo, do tipo série de casos, baseado em busca ativa em prontuários digitais. Utilizaram-se instrumentos validados para diagnóstico e avaliação clínica (Childhood Autism Rating Scale - CARS e Autism Treatment Evaluation Checklist - ATEC), além de roteiro semiestruturado fundamentado na Case Report (CARE checklist), permitindo a coleta de dados essenciais sobre a evolução dos pacientes que faziam uso complementar do óleo de cannabis. Resultados: Dos cinco pacientes, três eram meninos e duas meninas, entre 5 e 11 anos. Dois foram classificados com autismo grave e três com autismo leve a moderado. A média de idade ao diagnóstico foi de 42,6 meses, e o uso de CBD durou, em média, 7,4 meses. Todos apresentaram melhora expressiva em sintomas como agressividade, insônia, hiperatividade, interação social, comportamentos repetitivos, seletividade alimentar e concentração. As medicações associadas incluíram risperidona, clorpromazina, lamotrigina e topiramato, sendo a risperidona a mais utilizada. Conclusão: O óleo de cannabis rico em CBD demonstrou efeitos terapêuticos positivos em pacientes com sintomas persistentes do TEA, sem registro de eventos adversos relacionados ao seu uso inicial.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 85, e295805
Full Spectrum Cannabis Oil for the treatment of chronic pain and sleep dysfunction in myofascial temporomandibular disorder: a case report
Medicinal cannabis has been the subject of extensive research, with recent studies demonstrating its potential in managing chronic pain and enhancing quality of life. This case report examines the use of medicinal cannabis in a patient treated at the School of Dentistry of Araçatuba (FOA-UNESP). The patient, a 28-year-old female with no comorbidities, presented with chronic muscular TMD and reported poor sleep quality. Full-spectrum cannabis oil (1:1 ratio of THC to CBD), was prescribed for a period of 60 days, with a maximum dosage of 10 drops per day. Pain intensity was measured using the Visual Analog Scale (VAS), while sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Evaluations were conducted at three intervals: baseline, day 30, and day 60. To ensure patient safety, pre- and post-treatment blood tests were performed, and dosage adjustments were made every three days under the supervision of the study’s medical team. The results revealed significant improvements in pain management, with the patient’s orofacial pain score decreasing from 7 to 3 on the NRS. Additionally, sleep quality improved, as reflected by a lower PSQI score (global sleep quality at level 6 at the end), indicating more restorative sleep. Throughout the treatment period, the patient experienced mild side effects, including drowsiness and gastrointestinal discomfort, which were effectively managed through dosage modifications. In conclusion, full-spectrum cannabis oil shows promise as a therapeutic strategy for managing orofacial pain and improving sleep quality, providing significant relief in conditions where other interventions are ineffective or poorly tolerated. Further research is warranted to better understand the therapeutic mechanisms and potential side effects of medicinal cannabis in the management of chronic pain and related conditions.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 85, e295805
Open AccessFull Spectrum Cannabis Oil for the treatment of chronic pain and sleep dysfunction in myofascial temporomandibular disorder: a case report
Medicinal cannabis has been the subject of extensive research, with recent studies demonstrating its potential in managing chronic pain and enhancing quality of life. This case report examines the use of medicinal cannabis in a patient treated at the School of Dentistry of Araçatuba (FOA-UNESP). The patient, a 28-year-old female with no comorbidities, presented with chronic muscular TMD and reported poor sleep quality. Full-spectrum cannabis oil (1:1 ratio of THC to CBD), was prescribed for a period of 60 days, with a maximum dosage of 10 drops per day. Pain intensity was measured using the Visual Analog Scale (VAS), while sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Evaluations were conducted at three intervals: baseline, day 30, and day 60. To ensure patient safety, pre- and post-treatment blood tests were performed, and dosage adjustments were made every three days under the supervision of the study’s medical team. The results revealed significant improvements in pain management, with the patient’s orofacial pain score decreasing from 7 to 3 on the NRS. Additionally, sleep quality improved, as reflected by a lower PSQI score (global sleep quality at level 6 at the end), indicating more restorative sleep. Throughout the treatment period, the patient experienced mild side effects, including drowsiness and gastrointestinal discomfort, which were effectively managed through dosage modifications. In conclusion, full-spectrum cannabis oil shows promise as a therapeutic strategy for managing orofacial pain and improving sleep quality, providing significant relief in conditions where other interventions are ineffective or poorly tolerated. Further research is warranted to better understand the therapeutic mechanisms and potential side effects of medicinal cannabis in the management of chronic pain and related conditions.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 84, e290305
Cannabis oil in treating Parkinson’s disease: improvement of motor and non-motor symptoms: a case report
Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in the production of dopamine. Medication with levodopa becomes less effective as the disease progresses. Despite the excellent results observed in clinical practice with the medicinal use of Cannabis in the treatment of PD, the level of scientific evidence is still limited due to the small number of studies published in this field. We present the case of a 77-year-old man diagnosed 22 years ago with PD in an advanced stage, with significant bradykinesia, tremor, and rigidity along with the inability to maintain an upright position and walk, exacerbated by a femur fracture. He also had advanced dysphagia, resulting in a gastrostomy. Although lucid, he showed no interest in conversation and tended to become depressed and isolated. He used Prolopa® with no satisfactory therapeutic response. After starting treatment with Cannabis sativa oil, he is now able to walk around the house frequently and eat pasty food regularly without choking or broncho-aspiration episodes. There has also been a significant improvement in non-motor symptoms; he is more active, cheerful, communicative, and attentive to his surroundings. Further studies are needed to elucidate these results and the mechanisms of action of cannabinoids through which they exert possible neuroprotective and neuroreparative effects. These compelling results suggest that cannabis oil may offer a valuable and effective therapeutic option for individuals with Parkinson's disease.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 84, e290305
Open AccessCannabis oil in treating Parkinson’s disease: improvement of motor and non-motor symptoms: a case report
Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in the production of dopamine. Medication with levodopa becomes less effective as the disease progresses. Despite the excellent results observed in clinical practice with the medicinal use of Cannabis in the treatment of PD, the level of scientific evidence is still limited due to the small number of studies published in this field. We present the case of a 77-year-old man diagnosed 22 years ago with PD in an advanced stage, with significant bradykinesia, tremor, and rigidity along with the inability to maintain an upright position and walk, exacerbated by a femur fracture. He also had advanced dysphagia, resulting in a gastrostomy. Although lucid, he showed no interest in conversation and tended to become depressed and isolated. He used Prolopa® with no satisfactory therapeutic response. After starting treatment with Cannabis sativa oil, he is now able to walk around the house frequently and eat pasty food regularly without choking or broncho-aspiration episodes. There has also been a significant improvement in non-motor symptoms; he is more active, cheerful, communicative, and attentive to his surroundings. Further studies are needed to elucidate these results and the mechanisms of action of cannabinoids through which they exert possible neuroprotective and neuroreparative effects. These compelling results suggest that cannabis oil may offer a valuable and effective therapeutic option for individuals with Parkinson's disease.
- Top Cited PapersOpen Access
- 1 January 2024
- Published by EDITORA SCIENTIFIC in Trends in Psychiatry and Psychotherapy
- Vol. 46 (AheadOfPri)
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial
Trends Psychiatry Psychother, vol.0, nAheadOfPrint, p.0-0, 2022
- 1 January 2024
- Published by EDITORA SCIENTIFIC in Trends in Psychiatry and Psychotherapy
- Vol. 46 (AheadOfPri)
Top Cited PapersOpen AccessEvaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial
Trends Psychiatry Psychother, vol.0, nAheadOfPrint, p.0-0, 2022